Biogen Idec inc Earnings Were Great. Here's Why the Stock Tumbled Anyway

There's nothing like the disclosure of a side effect to ruin a perfectly good earnings report. Despite meeting analyst expectations on revenue, and beating on the earnings-per-share side, Biogen Idec traded down more than 10% at one point today after announcing that a patient taking its oral multiple sclerosis drug Tecfidera contracted progressive multifocal leukoencephalopathy, or PML.
Read more »

Labels: Biogen, PML (Progressive Multifocal Leukoencephalopathy), TECFIDERA, Tysabri

Biogen unveils study results confirming effectiveness of new MS treatment Plegridy

Kate Dawson, VP of Medical
       Affairs at Biogen

Biogen presented follow-up data from the second year of patients taking Plegridy, a once-a-month or once-every-other-week injected drug awaiting an approval decision in the U.S. as well as Europe. In the study, Plegridy was shown to continue helping patients manage relapses versus a placebo.

U.S. regulators accepted Biogen’s application for approval of Plegridy last July, and recently extended its deadline to approve the drug by three months. A decision is expected in coming months.
Read more »

Labels: Biogen, Plegridy

Biotech Gets A Lift On Popular Drug, Strong Pipeline

The success of Biogen Idec's oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder.
Read more »

Labels: Biogen, Rituxan, TECFIDERA, Tysabri

Biogen profit rises as Tecfidera shines

Read more »

Labels: Biogen, TECFIDERA, Tysabri

Biogen Idec to Present New Clinical Data from Its Neurology Portfolio of Drugs at AAN Annual Meeting

Read more »

Labels: Ampyra, Biogen, TECFIDERA, Tysabri

TECFIDERA SUCCEEDS IN PROTECTING BIOGEN'S MS MARKET SHARE FROM NOVARTIS' GILENYA

Biogen's Tecfidera is on its way to blockbuster status in the highly competitive multiple sclerosis indication. That's great news for Biogen, which needed the drug to succeed in order to protect its multibillion-dollar multiple sclerosis drug franchise.

The MS treatment market has previously been dominated by Biogen's Avonex and Tysabri, and Teva Pharmaceutical's Copaxone -- blockbuster drugs delivered by injection. Combined, those drugs generated sales of $8 billion in 2012. But, a new generation of drugs and upcoming patent expiration for Copaxone are disrupting current treatment protocols and shifting demand to new oral drugs including Novartis' Gilenya and Sanofi's  Aubagio.
Read more »

Labels: Aubagio, Biogen, Copaxone, Gilenya, TECFIDERA, Tysabri

Biogen Idec Inc, the maker of MS drugs Avonex, Tysabri and Tecfidera, boosted its 2013 forecast after Tecfidera sales topped analysts’ third-quarter estimates.

Revenue this year will grow by 23 percent to 25 percent, with adjusted earnings of $8.65 to $8.85 a share, the Weston, Massachusetts-based drugmaker said today in a statement. The company previously had projected revenue gaining 22 percent to 23 percent and adjusted earnings of $8.25 to $8.50 a share.
Read more »

Labels: Biogen, TECFIDERA, Tysabri

Sales of Biogen's multiple sclerosis pill Tecfidera are higher than anyone predicted

"We believe the continued growth of Tecfidera is a testament to its value to patients and physicians, and we are pleased with how it has complemented our robust portfolio of MS therapies," CEO George Scangos said in a statement.

Read more »

Labels: Aubagio, Biogen, Gilenya, TECFIDERA, Tysabri